The9 Ltd
NCTY
TeraWulf
WULF
Bit Digital
BTBT
BTCS Inc
BTCS
Abits
ABTS
US Stock MarketDetailed Quotes
ANRO Alto Neuroscience
- 2.414
- -0.086-3.46%
Trading Mar 27 15:47 ET
65.34MMarket Cap-1.06P/E (TTM)
2.545High2.370Low188.02KVolume2.540Open2.500Pre Close456.74KTurnover0.96%Turnover RatioLossP/E (Static)27.07MShares17.55052wk High0.43P/B47.07MFloat Cap2.37052wk Low--Dividend TTM19.50MShs Float24.000Historical High--Div YieldTTM7.00%Amplitude2.370Historical Low2.429Avg Price1Lot Size
Market Insights
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Alto Neuroscience Stock Forum
Alto Neuroscience Secures 4-Year Cash Runway as Multiple Phase 2 Trials Advance
The commercial potential is noteworthy for several reasons:
The treatment-resistant depression market represents approximately 30% of MDD patients, creating a substantial addressable market for adjunctive therapies.
The biomarker-guided approach could significantly improve treatment outcomes by identifying likely responders, potentially commanding premium pricing compared to traditional antidepressants.
EEG biomarkers provide an objective, m...
Revolutionary Depression Treatment Patent: How Alto's EEG Biomarker Could Transform Patient Care
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial
Wednesday, 12th February at 8:03 am
– Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker population of ~200 patients in the final analysis sample –
– Topline results are expected in mid-2026 –
– The company recently reported an estimated preliminary 2024 year-end cash balance of approximately ...
Clinical Trial Success: Alto's Novel Depression Treatment Hits Key Milestone in Phase 2b Study
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
Wednesday, 11th December at 8:03 am
– Data generated from Alto's precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion –
– New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for...
<- Blackrock ->
$Alto Neuroscience (ANRO.US)$
sec.gov/Archive...
#myANROanalysis
No comment yet